May 17, 2019 – Jackson, MI
Carmelina Gordon, M.D., a Vitreoretinal Surgeon, has been proudly serving patients at the Lansing and Jackson Specialty Eye Institute offices for over 15 years. Because retinal care is vital to a patient’s health and quality of life, Dr. Gordon maintains a strong focus on the latest technology, to assure that her patients are given the best treatment options to preserve their vision. Her dedication to research and clinical studies for retinal conditions has earned her a prestigious reputation in the medical field.
On behalf of her fellow VISTA and VIVID investigators, Dr. Carmelina Gordon presented a post hoc analysis of these 2 trials to compare the incidence of vision threatening complications due to diabetic retinopathy in patients treated with Eylea versus standard laser. The results of this analysis were presented for the first time during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Vancouver, Canada this past week. ARVO meetings are attended by more than 11,000 U.S. and international basic and clinical vision researchers.
The VISTA and VIVID studies are two pivotal, phase 3, randomized, multi center trials performed in the U.S. (VISTA) and the rest of the world (VIVID) that led to the FDA approval of the drug, Eylea, for treatment of diabetic macular edema.
Diabetic retinopathy is the most common cause of vision loss among working-age adults. This complication affects the retina of the eye and can lead to blindness. The longer a person has diabetes, the greater the chance of developing diabetic retinopathy. People who developed diabetes during childhood are most at risk of being stricken with diabetic retinopathy.
Specialty Eye Institute began in 1978 when Paul H. Ernest, M.D., the company’s founder opened Jackson Eye Center in Jackson, Michigan. Since then, the company has grown into a multi-specialty ophthalmology practice with 23 doctors in 10 locations throughout Michigan and Ohio. We strive to provide the highest level of ophthalmic care at an affordable price.